Clinical trial · Phase 2
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
N Engl J Med · 2023
42%Objective response
Studies and guidelines: Bile duct and gallbladder cancer
6 items with a structured summary · Bile duct and gallbladder cancer: the complete guide
Clinical trial · Phase 3
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Lancet Oncol · 2021
6.2 vs 5.3 monthsMedian overall survival
Clinical trial · Phase 2
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Lancet Oncol · 2020
35.5%Objective response (FGFR2 cohort)
Clinical trial · Phase 3
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
Lancet Oncol · 2019
Median 51.1 vs 36.4 monthsOverall survival (intention to treat)
Clinical trial · Phase 2b
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Lancet Oncol · 2023
41.3%Confirmed objective response (cohort 1)
Clinical trial · Phase 3
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Lancet Oncol · 2020
2.7 vs 1.4 monthsMedian progression-free survival (independent review)
Nothing found.